LIVE UPDATES
AFRICA (NAN) - The West African Health Organisation (WAHO), in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) and national task forces from five countries, convened on Thursday to further efforts in creating a vaccine for Lassa fever.
The inaugural meeting and the launch of the Lassa Fever Coalition Governing Entity (LFGE), hosted by the Federal Ministry of Health and Social Welfare in Abuja, represented a crucial advancement in tackling the persistent threat of Lassa fever in the region.
The coalition aims to develop, fairly distribute, and implement an effective Lassa fever vaccine, while also addressing urgent needs such as public awareness initiatives, training health workers, and ensuring access to life-saving treatments for at-risk populations.
Dr. Melchior Aissi, Director General of WAHO, characterized Lassa fever as a zoonotic disease that has affected West Africa for over five decades, leading to considerable morbidity and mortality, especially among healthcare professionals.
“Despite therapeutic options, the lack of a preventive vaccine has rendered the disease a recurring issue,” he stated.
Aissi emphasized the necessity of promoting scientific collaboration, raising awareness among political leaders, and ensuring the vaccine is affordable and accessible.
He also praised the backing of ECOWAS Heads of State and development partners in furthering WAHO’s agenda, which includes bolstering health systems, improving epidemic preparedness, and encouraging investment in research and innovation.
“Efforts are in progress to mobilize resources, guarantee fair distribution of health products, and cultivate a resilient healthcare workforce capable of tackling both emerging and existing health challenges,” he added.
Dr. Richard Hatchard, CEO of CEPI, noted significant advancements since the initiation of the Lassa fever vaccine program in 2018. “Nigeria has always been pivotal to these efforts as the epicenter of Lassa fever due to its high incidence of cases,” he remarked.
Hatchard disclosed that Phase II field trials are currently taking place in Nigeria, Liberia, and Sierra Leone, with previous trials conducted in Ghana. He underscored the importance of comprehending the epidemiology of Lassa fever throughout the region to effectively target vaccine trials.
Prof. Muhammad Pate, Coordinating Minister of Health and Social Welfare, highlighted the coalition’s commitment to advancing vaccine development and enhancing public health measures.
He pointed out the necessity for equity, ensuring that vulnerable groups such as women, children, and health workers benefit from the coalition’s initiatives.
“Ongoing collaboration among national, regional, and global partners is vital for establishing inclusive and resilient health systems,” Pate stated.
Dr. Catherine Cooper, Chief Medical Officer in Liberia, revealed that improved surveillance has identified a rise in Lassa fever cases across various regions in the country.
She emphasized the need for regional coordination to ensure a comprehensive strategy for vaccine development and survivor care.
In Sierra Leone, Dr. Mohamed Vandi, Deputy Executive Director of the National Public Health Agency, discussed advancements in enhancing laboratory capabilities for faster diagnosis of suspected cases.
However, he acknowledged challenges in rural areas, including delays in sample transport and result communication.
“Community awareness programs have been crucial in educating the public about preventive measures, such as proper food storage and sanitation, to minimize exposure to infected rodents,” Vandi stated.
Dr. Jide Idris, Director-General of the NCDC, stressed the significance of collaboration with institutions and researchers to foster interest and government support for scientific research.
He noted that public health activities are research-driven, involving data collection and expert collaboration, which are essential for addressing health challenges.
He highlighted the need for equitable sharing of benefits arising from global scientific endeavors, ensuring that all regions, including Africa, have fair access to innovations, technologies, and products.
The coalition symbolizes a unified effort to combat Lassa fever in West Africa, merging scientific innovation with a commitment to equitable healthcare delivery.
While challenges persist, the combined efforts of national governments, regional organizations, and international partners provide hope for a healthier and more resilient future for the region.
